CRISPR Gene Editing Market Size Projected to Surpass $2 Billion by 2024 Amid Increasing Demand for Genetic Treatments - Long-term Forecast to 2028 and 2033
15 août 2024 09h57 HE
|
Research and Markets
Dublin, Aug. 15, 2024 (GLOBE NEWSWIRE) -- The "Global CRISPR Gene Editing Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The CRISPR gene editing market has...
CRISPR and Cas Gene Global Research Report 2024 | Now Available
01 août 2024 06h10 HE
|
Research and Markets
Dublin, Aug. 01, 2024 (GLOBE NEWSWIRE) -- The "CRISPR and Cas Gene Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The crispr and cas gene market size has...
Adeno-associated Virus Gene Therapy Market Report 2024-2034: Epidemiology, Industry Trends and Forecasts
21 juin 2024 06h05 HE
|
Research and Markets
Dublin, June 21, 2024 (GLOBE NEWSWIRE) -- The "Adeno-associated Virus Gene Therapy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034" report has been...
CRISPR Therapies Market Research 2024: Pipeline Analysis, Therapeutic Assessment, Unmet Needs, Impact of Drugs
14 juin 2024 06h15 HE
|
Research and Markets
Dublin, June 14, 2024 (GLOBE NEWSWIRE) -- The "CRISPR therapies - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.This "CRISPR Therapies - Pipeline...
Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool
29 mai 2024 15h27 HE
|
Recursion Pharmaceuticals
SALT LAKE CITY, May 29, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today published in Nature...
Cytosurge's CellEDIT Workflow, based on its Proprietary FluidFM® Technology, Receives Validation in Peer-Reviewed Publication
29 mai 2024 08h30 HE
|
Cytosurge AG
CellEDIT uses FluidFM for precise nuclear CRISPR/Cas9 injection, boosting efficiency by controlling RNP amounts, preserving traits in edited CHO-K1 cells.
Cytosurge's CellEDIT Workflow, based on its Proprietary FluidFM® Technology, Receives Validation in Peer-Reviewed Publication
29 mai 2024 02h30 HE
|
Cytosurge AG
CellEDIT uses FluidFM for precise nuclear CRISPR/Cas9 injection, boosting efficiency by controlling RNP amounts, preserving traits in edited CHO-K1 cells.
Global Gene Editing Tools Market Report 2024: A $3.83 Billion Market by 2034, with a CAGR of 18.84% During 2024-2034
27 mai 2024 04h13 HE
|
Research and Markets
Dublin, May 27, 2024 (GLOBE NEWSWIRE) -- The "Global Gene Editing Tools Market" report has been added to ResearchAndMarkets.com's offering.The global gene editing tools market accounted for USD...
Global Cell Therapy and Gene Therapy Market Report 2023-2029
13 mai 2024 11h34 HE
|
Research and Markets
Dublin, May 13, 2024 (GLOBE NEWSWIRE) -- The "Cell Therapy and Gene Therapy Markets (Markets by Disease Type), 2023-2029" report has been added to ResearchAndMarkets.com's offering.A newly released...
Gene Editing Collaboration, R&D, and Licensing Deals Analysis Report 2024 with Directory of 354 Agreements Signed Since 2016
07 mai 2024 07h38 HE
|
Research and Markets
Dublin, May 07, 2024 (GLOBE NEWSWIRE) -- The "Gene Editing Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.Gene Editing Collaboration and...